Combination administration of SHP2 and MEK inhibitor can markedly suppress the proliferation of KRAS mutant NSCLC [63], and even reverse the drug resistance to first-generation EGFR-TKIs [64]. Here, PTPN11 is linked to non-small cell lung carcinoma.